Core Viewpoint - The collaboration agreement between Neurocrine and the company for the development of NLRP3 inhibitors represents a significant opportunity for the company, with a total potential value of $881.5 million [1] Group 1: Agreement Details - Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize the NLRP3 inhibitors outside Greater China, while the company retains these rights within Greater China [1] - The agreement includes upfront payments and potential milestone payments related to research and sales progress, enhancing the financial outlook for the company [1] Group 2: Financial Implications - The total potential value of the agreement is estimated at $881.5 million, indicating a substantial financial opportunity for the company [1] - The agreement may lead to further milestone payments as Neurocrine progresses in development and commercialization [1] Group 3: Research Collaboration - The agreement also encompasses research collaboration between the parties to further develop NLRP3-related technologies, which could enhance the company's product pipeline [1]

Core Viewpoint - The stock of药捷安康-B (02617) opened over 6% higher following the announcement of a collaboration agreement with Neurocrine Biosciences to develop NLRP3 inhibitors for various diseases, indicating positive market sentiment towards the partnership [1] Group 1: Partnership Details - On November 3,药捷安康-B announced a licensing and research collaboration agreement with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors [1] - Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize the NLRP3 drug platform outside Greater China, while the company retains rights within Greater China [1] - The agreement has a total potential value of $881.5 million, including upfront payments and milestone payments related to development and commercialization progress [1] Group 2: Market Reaction - Following the announcement, the stock price of药捷安康-B rose by 6.58%, reaching HKD 195.9, with a trading volume of HKD 6.5627 million [1]

Core Viewpoint - The announcement of a collaboration agreement between Neurocrine Biosciences and the company for the development of NLRP3 inhibitors has positively impacted the stock price, leading to a significant increase in share value [1] Group 1: Agreement Details - On November 3, the company announced a collaboration agreement with Neurocrine Biosciences for the development of NLRP3 inhibitors aimed at treating various diseases [1] - Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize the NLRP3 drug platform outside of Greater China, while the company retains these rights within Greater China (Mainland, Hong Kong, Taiwan, Macau) [1] - The agreement has a total potential value of $881.5 million, which includes upfront payments and milestone payments related to development and commercialization progress [1] Group 2: Financial Impact - Following the announcement, the company's stock opened over 6% higher and was trading at HKD 195.9, reflecting a 6.58% increase with a trading volume of HKD 6.5627 million [1] - The potential financial benefits from the agreement could significantly enhance the company's revenue streams through milestone payments as development progresses [1]